Abbott Labs Sells Developed Markets Generics Unit

July 14 (Bloomberg) -- Marshall Sonenshine, chairman and managing partner at Sonenshine Partners, and Jonathan Golub, chief U.S. market strategist at RBC Capital Markets, examine Abbott Laboratories selling its developed markets generic drug unit to Mylan in a deal worth $5.3 Billion and what it means to the current M&A market. They speak on “Bloomberg Surveillance.”
When the Dollar's Too Strong: Reaction to Yellen's Speech
50:32 - David Mazza, Carl Riccadonna and Cliff Noreen discuss Janet Yellen's speech. They speak with Alix Steel on "Street Smart." (Source: Bloomberg)
  • Yellen: Rise in Rates Appropriate Over Next Few Years
  • Yellen Says Rate Rise May Be Warranted Later This Year
  • Iran Nuclear Deal Would Be Negative for Oil, Gheit Says